Cabozantinib in advanced renal cell carcinoma: A phase II, open‐label, single‐arm study of Japanese patients-Reference-Cited by-同舟云学术

Cabozantinib in advanced renal cell carcinoma: A phase II, open‐label, single‐arm study of Japanese patients

Published:2020-08-12 Issue:11 Volume:27 Page:952-959
ISSN:0919-8172
Container-title:International Journal of Urology
language:en
Short-container-title:Int. J. Urol.

Author:

Tomita Yoshihiko¹,Tatsugami Katsunori²,Nakaigawa Noboru³,Osawa Takahiro⁴,Oya Mototsugu⁵,Kanayama Hiroomi⁶,Nakayama Kondoh Chihiro⁷,Sassa Naoto⁸,Nishimura Kazuo⁹,Nozawa Masahiro¹⁰,Masumori Naoya¹¹,Miyoshi Yasuhide¹²,Kuroda Shingo¹³,Tanaka Shingo¹⁴,Kimura Akiko¹⁵,Tamada Satoshi¹⁶

Affiliation:

1. Department of Urology, Molecular Oncology Niigata University Graduate School of Medical and Dental Sciences Niigata Japan

2. Department of Urology Graduate School of Medical Sciences Kyushu University Fukuoka Japan

3. Department of Urology Yokohama City University Graduate School of Medicine Yokohama Japan

4. Department of Renal and Genitourinary Surgery Hokkaido University Sapporo Japan

5. Department of Urology Keio University School of Medicine Tokyo Japan

6. Department of Urology Graduate School of Biomedical Sciences Tokushima University Tokushima Japan

7. Department of Medical Oncology Toranomon Hospital Tokyo Japan

8. Department of Urology Nagoya University Graduate School of Medicine Nagoya Japan

9. Department of Urology Osaka International Cancer Institute Osaka Japan

10. Department of Urology Kindai University Faculty of Medicine Osaka‐sayama Japan

11. Department of Urology Sapporo Medical University School of Medicine Sapporo Japan

12. Department of Urology and Renal Transplantation Yokohama City University Medical Center Yokohama Japan

13. Biostatistics Japan Development Center Takeda Pharmaceutical Company Limited Osaka Japan

14. PRA Health Sciences Company Limited Osaka Japan

15. Oncology Clinical Science Oncology Therapeutic Area Unit for Japan and Asia Takeda Pharmaceutical Company Limited Tokyo Japan

16. Department of Urology Osaka City University Graduate School of Medicine Osaka Japan

Funder

Takeda Pharmaceutical

Publisher

Wiley

Subject

Urology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/iju.14329

Reference23 articles.

1. Cancer Information Service.Cancer statistics in Japan ’18. [Cited 26 Jul 2019]. Available from URL:https://ganjoho.jp/en/professional/statistics/brochure/2018_en.html

2. International Variations and Trends in Renal Cell Carcinoma Incidence and Mortality

3. Renal Cell Tumors: Understanding Their Molecular Pathological Epidemiology and the 2016 WHO Classification

4. Epidemiology of renal cancer in developing countries: Review of the literature

5. Overproduction of Vascular Endothelial Growth Factor Related to von Hippel-Lindau Tumor Suppressor Gene Mutations and Hypoxia-Inducible Factor-1α Expression in Renal Cell Carcinomas.

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of second-line cabozantinib after immuno-oncology combination therapy for advanced renal cell carcinoma: Japanese multicenter retrospective study;Scientific Reports;2023-11-23

2. Cost-effectiveness analysis of cabozantinib compared with everolimus, axitinib, and nivolumab in subsequent line advanced renal cell carcinoma in Japan;Journal of Medical Economics;2023-08-12

3. Real-world efficacy and safety of cabozantinib following immune checkpoint inhibitor failure in Japanese patients with advanced renal cell carcinoma;Japanese Journal of Clinical Oncology;2023-07-29

4. Electronic patient-reported outcome (e-PRO) monitoring for adverse event management during cabozantinib treatment in patients with advanced renal cell carcinoma: protocol for a three-arm, randomised, multicentre phase II trial (e-PRO vs paper-PRO or usual care);BMJ Open;2023-07

5. Cabozantinib-induced serum creatine kinase elevation and rhabdomyolysis: a retrospective case series;Cancer Chemotherapy and Pharmacology;2023-06-28